Oxford Drug Design is an innovative biotechnology company spun out from Professor Graham Richards’ group at the University of Oxford.The company has developed rapid, stateof-the-art virtual screening and ligand analogue searching technologies.
Building on this platform, the company is now applying machine learning techniques such as neural networks and topological data analysis to help further the drug discovery process. Utilising this technology, the company has developed a number of novel antibiotics programmes.
|Modality||Digital & Small Molecule|
|Partner||CARB-x, Innovate UK|
|Investment Portfolio||Fund Investment|
|Co-Investors||IP Group PLC, Meltwind, Business Angels|